Eisai Oncology to Present Data Analyses on Halaven® (eribulin) at 36th Annual San Antonio Breast Cancer Symposium

Eisai Oncology to Present Data AnalysesEisai Oncology to Present Data Analyses on Halaven® (eribulin) at 36th Annual San Antonio Breast Cancer Symposium PR Newswire HATFIELD, England, December 5, 2013 Eisai announced today that four abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer Symposium. The meeting will be held 10-14 December 2013 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The studies highlight Eisai's current and ongoing clinical research efforts with eribulin and reinforce the company's commitment to the breast cancer community. "As part of Eisai's human health care mission, Eisai gives first thought to patients and their families by developing drugs for diseases with unmet medical need," said Kenichi Nomoto, Ph.D., President, Oncology Product Creation Unit at Eisai. "Nowhere is this more compelling than in oncology, one of Eisai's long-standing therapeutic areas of focus." The following Eisai abstracts have been accepted for presentation at this year's San Antonio Breast Cancer Symposium: Product/ Poster Number Abstract Name Eribulin Eribulin mesylate as first-line therapy for locally P3-13-05 recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study McIntyre et al.